NCT05127421

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 12 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open label extension period.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Ruxolitinib cream	Ruxolitinib cream 1.5% applied twice a day (BID)"
DRUG	Vehicle	Vehicle cream applied twice a day (BID) to affected areas

Timeline

• Start date: 2021-11-10
• Primary completion: 2023-08-03
• Completion: 2023-09-29
• First posted: 2021-11-19
• Last updated: 2024-08-15
• Results posted: 2024-08-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study